Ascentage Pharma Group International
AAPGNASDAQHealthcare● Active
$17.30
+$0.10(+0.58%)
Market Cap$1.6B
P/E Ratio—
52W High$48.45
52W Low$17.0001
Ascentage Pharma Group International (AAPG) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AAPG · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 24, 2026EPS Actual
-$0.65
Est. -$0.83 · +21.7%
Revenue
$0.05B
Est. $0.04B · +11.5%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 24, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
AAPG reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | -$0.43 | — | — | — | $0.05B | — |
| ▲ Q1 FY2026 | Mar 24, 2026 | -$0.83 | -$0.65 | +21.7% | $0.05B | $0.04B | +11.5% |
| — Q3 FY2025 | Aug 20, 2025 | — | -$0.96 | — | $0.03B | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | $0.02 | -$1.00 | -6134.6% | $0.02B | — | — |
| — Q3 FY2024 | Aug 22, 2024 | — | $0.31 | — | $0.12B | — | — |
| — Q2 FY2024 | Jun 30, 2024 | — | $0.30 | — | $0.11B | — | — |
| — Q4 FY2023 | Dec 31, 2023 | — | -$1.02 | — | $0.01B | — | — |
| — Q3 FY2023 | Aug 21, 2023 | — | -$0.81 | — | $0.02B | — | — |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
-$0.43
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 24, 2026Beat
EPS Actual
-$0.65
EPS Est.
-$0.83
EPS Surpr.
+21.7%
Revenue
$0.05B
Q3 FY2025
Aug 20, 2025
EPS Actual
-$0.96
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$1.00
EPS Est.
$0.02
EPS Surpr.
-6134.6%
Revenue
$0.02B
Q3 FY2024
Aug 22, 2024
EPS Actual
$0.31
EPS Est.
—
EPS Surpr.
—
Revenue
$0.12B
Q2 FY2024
Jun 30, 2024
EPS Actual
$0.30
EPS Est.
—
EPS Surpr.
—
Revenue
$0.11B
Q4 FY2023
Dec 31, 2023
EPS Actual
-$1.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q3 FY2023
Aug 21, 2023
EPS Actual
-$0.81
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-2.00 | $-2.00 | $-2.00 | 1 |
| Q3 FY2028 | $-2.00 | $-2.00 | $-2.00 | 1 |
| Q2 FY2028 | $-2.00 | $-2.00 | $-2.00 | 1 |
| Q1 FY2028 | $-3.59 | $-3.59 | $-3.59 | 1 |
| Q4 FY2027 | $-2.96 | $-2.96 | $-2.96 | 1 |
| Q3 FY2027 | $-5.74 | $-5.74 | $-5.74 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q3 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q2 FY2028 | $0.4B | $0.4B | $0.4B | 1 |
| Q1 FY2028 | $0.4B | $0.4B | $0.4B | 1 |
| Q4 FY2027 | $0.4B | $0.4B | $0.4B | 1 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 24, 2026 | +21.7% | $22.32 | $22.32 | +0.00% |
| — Q3 FY2025 | Aug 20, 2025 | — | $46.40 | $47.20 | +1.72% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -6134.6% | $18.37 | $20.20 | +9.96% |
| — Q3 FY2024 | Aug 22, 2024 | — | No price data | $17.38 | — |
| — Q2 FY2024 | Jun 30, 2024 | — | No price data | $17.38 | — |
| — Q4 FY2023 | Dec 31, 2023 | — | No price data | $17.38 | — |
| — Q3 FY2023 | Aug 21, 2023 | — | No price data | $17.38 | — |
| — Q2 FY2023 | Jun 30, 2023 | — | No price data | $17.38 | — |
Q1 FY2026+0.00%
Report Date
Mar 24, 2026
EPS Beat/Miss
+21.7%
Price Before
$22.32
Price After
$22.32
Q3 FY2025+1.72%
Report Date
Aug 20, 2025
EPS Beat/Miss
—
Price Before
$46.40
Price After
$47.20
Q1 FY2025+9.96%
Report Date
Mar 27, 2025
EPS Beat/Miss
-6134.6%
Price Before
$18.37
Price After
$20.20
Q3 FY2024—
Report Date
Aug 22, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$17.38
Q2 FY2024—
Report Date
Jun 30, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$17.38
Q4 FY2023—
Report Date
Dec 31, 2023
EPS Beat/Miss
—
Price Before
—
Price After
$17.38
Q3 FY2023—
Report Date
Aug 21, 2023
EPS Beat/Miss
—
Price Before
—
Price After
$17.38
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
—
Price After
$17.38
Avg Beat Reaction+0.00%
Avg Miss Reaction+9.96%
Beat Rate1 / 8 quarters
Largest Move+9.96% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AAPG ends December
Ascentage Pharma Group International (AAPG) most recently reported earnings on March 24, 2026 for Q1 FY2026, posting EPS of $-0.65 — beating the analyst consensus of $-0.83 by +21.7%. The next AAPG earnings date is expected around September 1, 2026.
Each quarter, investors track AAPG earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AAPG revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AAPG's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AAPG earnings · 5 questionsAscentage Pharma Group International's next earnings report is expected around September 1, 2026. AAPG typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AAPG historically reports after market close (AMC).
AAPG earnings datewhen is AAPG earningsAAPG next earnings datewhen does AAPG report earningsAAPG earnings calendar
▸ Source: FMP · Ascentage Pharma Group International SEC filings · US GAAP · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026